source
- Pharma access plans rise to 69% of late-stage drugs but gaps remain for non-communicable diseasesA new analysis shows that many large drug makers are expanding programs to make medicines available in low- and middle‑income markets, but progress is uneven across disease areas. Access plans now…
- Delix Therapeutics secures $100 million Series C to advance psychedelic pipelineDelix Therapeutics announced it has closed a $100 million Series C financing round. The capital will be used to accelerate development of its pipeline of psychedelic and neuroplastogen candidates…